LAVA-1266 is a potent bi-specific, T cell engager (bsTCE) that targets CD123+ tumor cells with Vγ9Vδ2-T cells using LAVA’s Gammabody ® platform. The bsTCE was designed to lyse CD123+ tumor cells with ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback